Figure 3
Sleep-stage distributions produced by the intraperitoneal administration of gelsemine in PSNL mice. (A) Time course of the changes in NREM sleep, REM sleep, and wakefulness in PSNL mice treated with gelsemine. Each circle represents the hourly mean amount of each stage. The horizontal open and filled bars on the x-axes indicate the 12 h light and 12 h dark periods, respectively. Data are expressed as mean±SEM (n=8). bP<0.05, cP<0.01 vs vehicle control group. (B) Dose-dependent effect of gelsemine on the total time spent in NREM sleep, REM sleep, and wakefulness for 3 h after administration in PSNL mice. Data are expressed as mean±SEM (n=8). bP<0.05, cP<0.01 vsvehicle-treated PSNL mice; eP<0.05 indicates significant differences among the gelsemine doses.
